Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies

Figures & data

Table 1. Characteristics and differences between excess weight and normal BMI

	Excess Weight (N = 64)	Normal BMI (N = 64)	P value
Age, median	69	68.5	P = .77
Sex
Female	19 (29.7%)	17 (26.5%)	P = .76
Male	45 (70.3%)	47 (73.5%)
Treatment
Nivolumab	43 (67.1%)	49 (76.5%)	P = .27
Pembrolizumab	21 (32.9%)	15 (23.5%)
Histology
(two most frequent) Adenocarcinoma	26 (40.6%)	29 (45.3%)	P = .50
Squamous carcinoma	20 (31.2%)	22 (34.3%)
ECOG PS
ECOG 0	9 (14.1%)	8 (12.5%)	P = .09
ECOG 1	41 (64.1%)	30 (46.9%)
ECOG 2	14 (21.8%)	26 (40.6%)
Smoking habit
Currently smokers	48 (75%)	53 (82.8%)	P = .45
Non smokers	15 (25%)	11 (18.2%)
Prior lines treatment No prior lines	16 (25%)	9 (14.1%)	P = .38
One prior line	26 (40.6%)	28 (43.7%)
Two or more prior lines	22 (34.4%)	27 (42.2%)
Immune-related Adverse Events
Yes	24 (37.%)	19 (29.7%)	P = .21
No	40 (62.5%)	45 (70.3%)
Hypertension
Yes	37 (57.8%)	19 (29.7%)	P = .001
No	27 (42.2%)	45 (70.3%)
Diabetes Mellitus
Yes	9 (14.1%)	12 (18.7%)	P = .47
No	55 (85.9%)	52 (81.3%)
Corticosteroid consumption
Yes	14 (21.9%)	7 (10.9%)	P = .09
No	50 (78.1%)	57 (89.1%)

* BMI: Body Mass Index

* ECOG PS: Eastern Cooperative Oncology Group Performance Status

Table 2. Relationship of objective radiological response (ORR) and excess weight in patients treated with Nivolumab or Pembrolizumab

	Excess weight (n = 64)	Normal weight (n = 64)
ORR	33 (51.5%)	16 (25%)	P < .001
No ORR	31 (48.5%)	48 (75%)

* ORR: Objective radiological response

Figure 1. Median progression-free survival according to BMI

Figure 2. Median progression-free survival according to BMI and development of irAEs

Table

IrAEs	immune-related adverse events
BMI	body mass
ORR	objective radiological response
PFS	progression free survival
SD	standard deviation
IQR	interquartile range
ECOG	eastern cooperative oncology group
NSCLC	non-small cell lung cancer
SCCHN	squamous cell carcinoma of the head and neck
HL	Hodgkin´s lymphoma
OR	odds ratio
HR	hazard ratio
CI	confidence interval
ICI	immune-checkpoint inhibitor